Serrapeptase: The Definitive Guide

What is serrapeptase?

Serrapeptase is a proteolytic enzyme also called serratiopeptidase. Supplements are sold by milligrams or enzyme-activity units, but these declarations are not interchangeable unless a product supplies a validated activity specification.

The most relevant human evidence concerns short-term swelling, restricted mouth opening and pain after third-molar surgery. Laboratory descriptions of protein or fibrin breakdown do not show that an oral supplement removes scar tissue, biofilms, arterial plaque or an existing clot.

Typical Serrapeptase Protocols

There is no RDA, AI or UL for serrapeptase. Trial regimens should not be generalized to unsupervised chronic use.

Activity and mass

Record both declared enzyme activity and milligrams. One cannot be inferred reliably from the other.

Co-treatment

Record paracetamol, anti-inflammatory medicines, antibiotics and rescue analgesics; they change what a result means.

Surgical context

Keep the procedure, postoperative day and measured endpoint attached to every observation.

Bleeding context

Record anticoagulants, antiplatelets, bleeding disorders, upcoming procedures and unusual bruising or bleeding.

What is serrapeptase commonly used for?

Serrapeptase is marketed for postoperative swelling, sinus symptoms, pain, scars, biofilms, circulation and “arterial cleaning.” The cited human studies directly address only short postoperative dental outcomes.

No cited trial shows that oral serrapeptase treats thrombosis, prevents cardiovascular events, clears an infection or remodels a mature scar. Suspected clot, stroke, heart attack or serious infection requires urgent medical care.

Which forms and labels matter?

Labels may use serrapeptase, serratiopeptidase, milligrams or activity units. Compare the complete enzyme identity, activity method, amount per capsule, number of capsules per dose, daily frequency, enteric coating, excipients and independent quality testing.

An enteric coating is a product feature, not proof of systemic absorption or clinical efficacy. A product with the same milligram amount as a study is not necessarily equivalent in enzyme activity.

What does the human evidence show?

Tamimi randomized 140 adults after impacted mandibular third-molar surgery; 133 completed. Both groups received paracetamol 1,000 mg three times daily for five days. Adding serratiopeptidase 10 mg three times daily improved measured swelling and maximal mouth opening on days four and five versus placebo. Reported pain did not differ, and no side effects or rescue medication use were recorded during the short follow-up. [1]

Al-Khateeb used a within-person crossover design in 24 healthy people undergoing two similar procedures. Serrapeptase 5 mg plus paracetamol 1,000 mg was compared with placebo plus paracetamol. Swelling and pain favored serrapeptase, while maximal mouth opening did not. The accessible abstract omits the administration frequency, limiting exact replication. [2]

Sivaramakrishnan pooled five small studies. Compared with corticosteroids, the estimate for mouth opening favored serratiopeptidase by 4.42 mm, while swelling did not differ significantly. Study scarcity prevented useful pooling for several other outcomes and comparators. [3]

Al-Moraissi randomized 60 people across oral serratiopeptidase 10 mg, oral dexamethasone 8 mg and submucosal chymotrypsin 5 mg. The abstract reported no significant between-group differences in pain, swelling or mouth opening through day five. It was an active-comparator study without placebo. [4]

How might it work?

Serrapeptase is a protease that can break peptide bonds under laboratory conditions. Proposed anti-inflammatory and fibrinolytic effects are biologically plausible hypotheses, but oral stability, absorption, tissue exposure and clinically meaningful systemic action are not established by the cited dental trials.

What are the risks and interactions?

Short trials cannot define uncommon or long-term harms. Proteolytic and proposed fibrinolytic activity raises concern around anticoagulants, antiplatelets, NSAIDs, bleeding disorders and surgery. Stop self-experimentation and seek care for black stools, vomiting blood, severe headache, weakness on one side, chest pain, shortness of breath or uncontrolled bleeding.

Allergic reactions and gastrointestinal symptoms are possible. Pregnancy, breastfeeding, children, liver or kidney disease and prolonged use remain poorly studied. Surgical teams need the exact product and last dose before a procedure.

Status in the United States and Canada

In the United States, serrapeptase is sold as a dietary supplement and is not approved to treat clots, cardiovascular disease, infection or postoperative complications.

In Canada, authorized natural health products have product-specific licence conditions. A licence does not establish equivalence to a cited trial or support replacing medical care.

What should be monitored?

Record product, lot, milligrams, activity units, each administration time, co-treatments, procedure date, pain score, swelling measure, mouth opening, bleeding and adverse symptoms. Keep clinician-directed monitoring separate from subjective symptom notes.

What happens after stopping?

No withdrawal syndrome or taper is established. A clinician should direct changes around surgery or prescribed anticoagulant, antiplatelet or anti-inflammatory therapy.

How should it be stored?

Follow the label for temperature and moisture. Keep the original container, lot and expiry date and store it out of children’s reach.

Community experiences

Anecdotes frequently omit activity units, enteric coating, co-treatments and objective measurements. A change in pain or swelling cannot demonstrate scar, plaque, biofilm or clot removal.

How does it compare with other approaches?

Standard postoperative care uses procedure-specific instructions and medicines with defined dosing and contraindications. Anticoagulants, antibiotics and treatments for cardiovascular disease have diagnosis-specific evidence and monitoring. Serrapeptase does not replace them.

Frequently asked questions

Is serrapeptase the same as serratiopeptidase?

The names are commonly used for the same proteolytic enzyme. The label still needs a clear activity and amount specification.

Did the largest cited trial show pain relief?

No. Swelling and mouth opening favored serratiopeptidase, but reported pain did not differ. [1]

Was 10 mg three times daily tested alone?

No. Tamimi used it with paracetamol 1,000 mg three times daily; the control used the same paracetamol plus placebo. [1]

Does it dissolve blood clots?

The cited human trials do not establish treatment of an acute or chronic clot.

Does it remove scar tissue or biofilms?

No cited human trial demonstrates those outcomes.

Can it be used before surgery?

Disclose it early to the surgical team. Bleeding uncertainty and procedure-specific decisions require clinical direction.

Glossary

Terms used in this guide.

Serratiopeptidase

Proteolytic enzyme also commonly called serrapeptase.

Protease

Enzyme that breaks peptide bonds in proteins under suitable conditions.

Trismus

Restricted mouth opening, measured in the cited surgical studies by maximal interincisal distance.

Adjunctive therapy

Treatment added to another intervention rather than tested alone.

Crossover study

Design in which participants receive more than one study condition at different times.

Fibrinolysis

Biological breakdown of fibrin in blood clots; laboratory activity does not establish clinical clot treatment.

How this guide was researched

This draft prioritizes randomized human studies with exact postoperative context and a systematic review. Evidence checked October 9, 2026.

How this guide was made

The research ledger preserves amount per administration, frequency, duration, co-treatment, comparator, endpoint, attrition and access limits.

Sources

Related guides